{"transactions":[{"id":759304,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T21:43:52.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of\none share of Exelixis, Inc. common stock (\"Common Stock\"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous\nservice through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs."}],"balance_after":1197595,"source":{"system":"sec-edgar","filing":"0000939767-26-000083","document":"wk-form4_1780091030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976726000083/wk-form4_1780091030.xml","form_type":"4"}},{"id":811374,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:15:09.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":17578,"price":2.56,"value":44999.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000.  The RSUs  vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":217578,"source":{"system":"sec-edgar","filing":"0001202098-26-000004","document":"form4-04092026_050404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120209826000004/form4-04092026_050404.xml","form_type":"4"}},{"id":873742,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:20.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001202098-26-000002","document":"form4-03022026_040315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120209826000002/form4-03022026_040315.xml","form_type":"4"}},{"id":1000920,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T00:12:53.000Z","date":"2025-11-12","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":43.55,"value":4355000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.55 to $43.58. Reporting Person undertakes to provide Exelixis, Inc., any security\nholder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in\nfootnote 1 to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,812 shares of Exelixis, Inc. common stock (\"Common Stock\") that will be issued to the Reporting Person upon vesting of restricted stock units (\"RSUs\"). Each RSU is the economic equivalent of one share of Common Stock."}],"balance_after":1189228,"source":{"system":"sec-edgar","filing":"0000939767-25-000137","document":"wk-form4_1763079170.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000137/wk-form4_1763079170.xml","form_type":"4"}},{"id":1100063,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59514,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, the Reporting Person elected to receive $2.95 per warrant, an amount equal to the Black Scholes Value (as defined in the Merger Agreement) for the warrants reported herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the Merger Agreement, the Reporting Person elected to receive $2.95 per warrant, an amount equal to the Black Scholes Value (as defined in the Merger Agreement) for the warrants reported herein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the Merger Agreement, the Reporting Person elected to receive $2.95 per warrant, an amount equal to the Black Scholes Value (as defined in the Merger Agreement) for the warrants reported herein."}],"balance_after":0,"derivative":{"exercise_price":7.46,"underlying":"Common Stock","underlying_shares":59514},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100062,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100061,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100060,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.36,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100059,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.45,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100058,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100057,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100056,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":8.8,"underlying":"Common Stock","underlying_shares":2325},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100055,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.4,"underlying":"Common Stock","underlying_shares":4650},"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100054,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":64635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, these Shares were converted into the right to receive the Offer Price. Additionally, each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive  (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1100053,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T21:11:47.000Z","date":"2025-06-25","kind":"other","planned":false,"acquired":false,"shares":976253,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, these Shares was tendered in exchange for the Offer Price."}],"balance_after":64635,"source":{"system":"sec-edgar","filing":"0000950170-25-091032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025091032/ownership.xml","form_type":"4"}},{"id":1129777,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T23:13:06.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":9812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock (\"Common Stock\").  The RSUs will vest as to 100% of the shares subject to the RSU award on May 29, 2026, subject to the Reporting Person's continuous service through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,650 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs."}],"balance_after":1289228,"source":{"system":"sec-edgar","filing":"0000939767-25-000088","document":"wk-form4_1748646758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000088/wk-form4_1748646758.xml","form_type":"4"}},{"id":1146201,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-17T00:57:50.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":15874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, representing the right to purchase a total of 15,874 shares of Common Stock, became fully exercisable on May 24, 2018."}],"balance_after":0,"derivative":{"exercise_price":20.5,"exercise_date":"2018-05-24","expiration_date":"2025-05-23","underlying":"Common Stock","underlying_shares":15874},"source":{"system":"sec-edgar","filing":"0000939767-25-000080","document":"wk-form4_1747443463.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000080/wk-form4_1747443463.xml","form_type":"4"}},{"id":1146200,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-17T00:57:50.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":20634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, representing the right to purchase a total of 20,634 shares of Common Stock, became fully exercisable on May 23, 2019."}],"balance_after":0,"derivative":{"exercise_price":19.77,"exercise_date":"2019-05-23","expiration_date":"2026-05-22","underlying":"Common Stock","underlying_shares":20634},"source":{"system":"sec-edgar","filing":"0000939767-25-000080","document":"wk-form4_1747443463.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000080/wk-form4_1747443463.xml","form_type":"4"}},{"id":1146199,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-17T00:57:50.000Z","date":"2025-05-15","kind":"sale","planned":false,"acquired":false,"shares":15874,"price":44.35,"value":704011.9,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 18,838 shares of Exelixis, Inc. common stock (\"Common Stock\") that will be issued to the Reporting Person upon vesting of restricted stock units (\"RSUs\"). Each RSU is the economic\nequivalent of one share of Common Stock."}],"balance_after":1279416,"source":{"system":"sec-edgar","filing":"0000939767-25-000080","document":"wk-form4_1747443463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000080/wk-form4_1747443463.xml","form_type":"4"}},{"id":1146198,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-17T00:57:50.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":15874,"price":20.5,"value":325417.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 18,838 shares of Exelixis, Inc. common stock (\"Common Stock\") that will be issued to the Reporting Person upon vesting of restricted stock units (\"RSUs\"). Each RSU is the economic\nequivalent of one share of Common Stock."}],"balance_after":1295290,"source":{"system":"sec-edgar","filing":"0000939767-25-000080","document":"wk-form4_1747443463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000080/wk-form4_1747443463.xml","form_type":"4"}},{"id":1146197,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-17T00:57:50.000Z","date":"2025-05-15","kind":"sale","planned":false,"acquired":false,"shares":20634,"price":44.35,"value":915117.9,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 18,838 shares of Exelixis, Inc. common stock (\"Common Stock\") that will be issued to the Reporting Person upon vesting of restricted stock units (\"RSUs\"). Each RSU is the economic\nequivalent of one share of Common Stock."}],"balance_after":1279416,"source":{"system":"sec-edgar","filing":"0000939767-25-000080","document":"wk-form4_1747443463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000080/wk-form4_1747443463.xml","form_type":"4"}},{"id":1146196,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-17T00:57:50.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":20634,"price":19.77,"value":407934.18,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 18,838 shares of Exelixis, Inc. common stock (\"Common Stock\") that will be issued to the Reporting Person upon vesting of restricted stock units (\"RSUs\"). Each RSU is the economic\nequivalent of one share of Common Stock."}],"balance_after":1300050,"source":{"system":"sec-edgar","filing":"0000939767-25-000080","document":"wk-form4_1747443463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000080/wk-form4_1747443463.xml","form_type":"4"}},{"id":1163289,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:30:13.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 30, 2025, the Reporting Person was granted 62,500 Restricted Stock Units (the \"Award\").  The Award vests in equal monthly installments over the 12 months from the date of grant."}],"balance_after":1040888,"source":{"system":"sec-edgar","filing":"0000950170-25-061119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017025061119/ownership.xml","form_type":"4"}},{"id":1227289,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:44:34.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option will vest in 36 equal monthly installments commencing on April 3, 2025, subject to the Reporting Person's continued services through each such date."}],"balance_after":90000,"derivative":{"exercise_price":0.49,"expiration_date":"2035-03-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-25-006568","document":"form4-03042025_090327.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000141588925006568/form4-03042025_090327.xml","form_type":"4"}},{"id":1493564,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T00:21:15.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":18838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 39,556 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of RSUs. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock."}],"balance_after":1279416,"source":{"system":"sec-edgar","filing":"0000939767-24-000102","document":"wk-form4_1717546868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000102/wk-form4_1717546868.xml","form_type":"4"}},{"id":1506105,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-05-22T23:23:03.000Z","date":"2024-05-20","kind":"exercise","planned":false,"acquired":false,"shares":11686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, representing the right to purchase a total of 11,686 shares of Exelixis, Inc. common stock, became fully exercisable on May 25, 2017."}],"balance_after":0,"derivative":{"exercise_price":19.57,"exercise_date":"2017-05-25","expiration_date":"2024-05-24","underlying":"Common Stock","underlying_shares":11686},"source":{"system":"sec-edgar","filing":"0000939767-24-000075","document":"wk-form4_1716420171.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000075/wk-form4_1716420171.xml","form_type":"4"}},{"id":1506104,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T23:23:03.000Z","date":"2024-05-20","kind":"sale","planned":false,"acquired":false,"shares":11437,"price":21,"value":240177.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.99 to $21.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1260578,"source":{"system":"sec-edgar","filing":"0000939767-24-000075","document":"wk-form4_1716420171.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000075/wk-form4_1716420171.xml","form_type":"4"}},{"id":1506103,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T23:23:03.000Z","date":"2024-05-20","kind":"exercise","planned":false,"acquired":true,"shares":11686,"price":19.57,"value":228695.02,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1272015,"source":{"system":"sec-edgar","filing":"0000939767-24-000075","document":"wk-form4_1716420171.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000075/wk-form4_1716420171.xml","form_type":"4"}},{"id":1506924,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T20:23:54.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":60000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-062932","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017024062932/ownership.xml","form_type":"4"}},{"id":1510911,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T20:38:06.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of\nStockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the\nCompany's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-061746","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017024061746/ownership.xml","form_type":"4"}},{"id":1574455,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-15T20:19:09.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":1.6,"value":400000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated March 11, 2024, with a closing date of March 14, 2024.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":978388,"source":{"system":"sec-edgar","filing":"0000950170-24-032213","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000095017024032213/ownership.xml","form_type":"4"}},{"id":1808365,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T20:28:24.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant, subject to the Reporting Person's continuous service."}],"balance_after":15000,"derivative":{"exercise_price":1.36,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-045634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919123045634/doc4.xml","form_type":"4"}},{"id":1857021,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T20:50:15.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":1.45,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-036766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919123036766/doc4.xml","form_type":"4"}},{"id":1870848,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T01:13:28.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":20718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on June 1, 2024, subject to the Reporting Person's continuous service through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1260329,"source":{"system":"sec-edgar","filing":"0000939767-23-000056","document":"wk-form4_1685754799.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000056/wk-form4_1685754799.xml","form_type":"4"}},{"id":1919450,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-14T20:39:06.000Z","date":"2023-04-13","kind":"grant","planned":false,"acquired":true,"shares":222198,"price":0.9001,"value":200000.4198,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities  were acquired from the Issuer pursuant to a Securities Purchase Agreement dated April 13, 2023. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Adjusted to reflect 10-to-1 reverse stock split effected June 28, 2022."}],"balance_after":728388,"source":{"system":"sec-edgar","filing":"0001209191-23-024329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919123024329/doc4.xml","form_type":"4"}},{"id":2228924,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-17T21:13:38.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":2255,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10095,"source":{"system":"sec-edgar","filing":"0001127602-22-017806","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760222017806/form4.xml","form_type":"4"}},{"id":2235644,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:18:30.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":90000,"derivative":{"exercise_price":0.27,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-035871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919122035871/doc4.xml","form_type":"4"}},{"id":2254297,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-28T01:19:34.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":19575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan.  The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 26, 2023, subject to the Reporting Person's continuous service through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 19,575 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1239611,"source":{"system":"sec-edgar","filing":"0000939767-22-000079","document":"wf-form4_165370075316969.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000079/wf-form4_165370075316969.xml","form_type":"4"}},{"id":2376039,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T01:22:08.000Z","date":"2022-02-22","kind":"sale","acquired":false,"shares":84515,"price":19.56,"value":1653113.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.37 to $19.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1220036,"source":{"system":"sec-edgar","filing":"0000939767-22-000031","document":"wf-form4_164575210475580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000031/wf-form4_164575210475580.xml","form_type":"4"}},{"id":2490369,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-01T21:12:11.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":2222222,"price":0.36,"value":799999.92,"ownership":{"direct":true},"balance_after":5061929,"source":{"system":"sec-edgar","filing":"0001209191-21-067264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919121067264/doc4.xml","form_type":"4"}},{"id":2646236,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-02T21:27:58.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":1275,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7840,"source":{"system":"sec-edgar","filing":"0001127602-21-021336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760221021336/form4.xml","form_type":"4"}},{"id":2667942,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T20:43:26.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":40000,"derivative":{"exercise_price":0.9877,"expiration_date":"2031-06-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-040620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919121040620/doc4.xml","form_type":"4"}},{"id":2691946,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-29T00:26:03.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":16424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan.  The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1304551,"source":{"system":"sec-edgar","filing":"0000939767-21-000063","document":"wf-form4_162224794151373.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000063/wf-form4_162224794151373.xml","form_type":"4"}},{"id":2715169,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014."}],"balance_after":0,"derivative":{"exercise_price":3.38,"exercise_date":"2014-05-29","expiration_date":"2021-05-28","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715168,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015."}],"balance_after":0,"derivative":{"exercise_price":3.13,"exercise_date":"2015-05-28","expiration_date":"2022-05-27","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715167,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016."}],"balance_after":0,"derivative":{"exercise_price":6.3,"exercise_date":"2016-05-26","expiration_date":"2023-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715166,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":5473,"price":25.01,"value":136879.73,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.99 to $25.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4."}],"balance_after":1288127,"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715165,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":40000,"price":3.38,"value":135200.0,"ownership":{"direct":true},"balance_after":1293600,"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715164,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":5075,"price":25,"value":126875.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.98 to $25.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4."}],"balance_after":1253600,"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715163,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":40000,"price":3.13,"value":125200.0,"ownership":{"direct":true},"balance_after":1258675,"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715162,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":10222,"price":24.95,"value":255038.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.93 to $24.97. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4."}],"balance_after":1218675,"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2715161,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-14T00:32:31.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":40000,"price":6.3,"value":252000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 15,538 shares of Exelixis, Inc. common stock (\"Common Stock\") that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1228897,"source":{"system":"sec-edgar","filing":"0000939767-21-000049","document":"wf-form4_162095233683684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976721000049/wf-form4_162095233683684.xml","form_type":"4"}},{"id":2893321,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-28T01:16:24.000Z","date":"2020-12-04","kind":"grant","acquired":true,"shares":793528,"price":0.6301,"value":500001.9928,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4 is being amended to correct the number of securities beneficially owned following the reported transaction."}],"balance_after":2839707,"source":{"system":"sec-edgar","filing":"0001209191-21-005768","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919121005768/doc4a.xml","form_type":"4/A","original_submission_date":"2020-12-07"}},{"id":2954954,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2020-12-07T21:21:50.000Z","date":"2020-12-04","kind":"grant","acquired":true,"shares":595146,"price":0.125,"value":74393.25,"ownership":{"direct":true},"balance_after":595146,"derivative":{"exercise_price":0.7464,"exercise_date":"2020-12-04","expiration_date":"2025-12-04","underlying":"Common Stock","underlying_shares":595146},"source":{"system":"sec-edgar","filing":"0001209191-20-061939","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919120061939/doc4.xml","form_type":"4"}},{"id":2954953,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-07T21:21:50.000Z","date":"2020-12-04","kind":"grant","acquired":true,"shares":793528,"price":0.6301,"value":500001.9928,"ownership":{"direct":true},"balance_after":1986729,"source":{"system":"sec-edgar","filing":"0001209191-20-061939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919120061939/doc4.xml","form_type":"4"}},{"id":2965114,"issuer":{"id":145040,"kind":"organization","name":"Eucrates Biomedical Acquisition Corp.","symbol":"EUCR"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2020-11-27T21:05:53.000Z","date":"2020-11-24","kind":"other","acquired":false,"shares":255094,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reflects the cancellation by the issuer of 255,094 Ordinary Shares, which were automatically surrendered to the issuer for no consideration by the reporting person pursuant to contractual arrangements with the issuer, triggered by the election by the underwriters of the issuer's initial public offering to partially exercise their option to purchase additional units and surrender their right to purchase the remainder of the option units."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reflects the cancellation by the issuer of 255,094 Ordinary Shares, which were automatically surrendered to the issuer for no consideration by the reporting person pursuant to contractual arrangements with the issuer, triggered by the election by the underwriters of the issuer's initial public offering to partially exercise their option to purchase additional units and surrender their right to purchase the remainder of the option units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares represent ordinary shares held by the issuer's sponsor, Eucrates LLC. The shares held by the sponsor are beneficially owned by each of Parag Saxena and Stelios Papadopoulos, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the sponsor, who have joint voting and dispositive power over the shares held by the sponsor. Mr. Saxena and Mr. Papadopoulos disclaim beneficial ownership over any securities owned by the sponsor in which they do not have any pecuniary interest."}],"balance_after":2619906,"source":{"system":"sec-edgar","filing":"0001104659-20-130016","document":"tm2037212-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000110465920130016/tm2037212-2_4.xml","form_type":"4"}},{"id":3104091,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T20:40:31.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":23250,"derivative":{"exercise_price":0.88,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001209191-20-037954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919120037954/doc4.xml","form_type":"4"}},{"id":3121177,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-06-05T21:20:19.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":1470,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6565,"source":{"system":"sec-edgar","filing":"0001127602-20-019030","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760220019030/form4.xml","form_type":"4"}},{"id":3137987,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-23T01:05:03.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":15538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan.  The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 21, 2021, subject to the Reporting Person's continuous service through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 25,855 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1188897,"source":{"system":"sec-edgar","filing":"0000939767-20-000097","document":"wf-form4_159019588550745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000097/wf-form4_159019588550745.xml","form_type":"4"}},{"id":3147829,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-05-16T00:18:15.000Z","date":"2020-05-13","kind":"exercise","acquired":false,"shares":120791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, representing the right to purchase a total of 120,791 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013."}],"balance_after":0,"derivative":{"exercise_price":5.82,"exercise_date":"2013-12-06","expiration_date":"2020-12-05","underlying":"Common Stock","underlying_shares":120791},"source":{"system":"sec-edgar","filing":"0000939767-20-000081","document":"wf-form4_158958827479443.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000081/wf-form4_158958827479443.xml","form_type":"4"}},{"id":3147828,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-16T00:18:15.000Z","date":"2020-05-13","kind":"exercise","acquired":true,"shares":120791,"price":5.82,"value":703003.62,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1173359,"source":{"system":"sec-edgar","filing":"0000939767-20-000081","document":"wf-form4_158958827479443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000081/wf-form4_158958827479443.xml","form_type":"4"}},{"id":3156997,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-05-09T01:18:37.000Z","date":"2020-05-08","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010."}],"balance_after":0,"derivative":{"exercise_price":5.92,"exercise_date":"2010-05-19","expiration_date":"2020-05-18","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000939767-20-000074","document":"wf-form4_158898709740775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000074/wf-form4_158898709740775.xml","form_type":"4"}},{"id":3156996,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-05-09T01:18:37.000Z","date":"2020-05-08","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013."}],"balance_after":0,"derivative":{"exercise_price":4.58,"exercise_date":"2013-05-23","expiration_date":"2020-05-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000939767-20-000074","document":"wf-form4_158898709740775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000074/wf-form4_158898709740775.xml","form_type":"4"}},{"id":3156995,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-09T01:18:37.000Z","date":"2020-05-08","kind":"sale","acquired":false,"shares":45000,"price":25.84,"value":1162800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.78 to $25.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4."}],"balance_after":1052568,"source":{"system":"sec-edgar","filing":"0000939767-20-000074","document":"wf-form4_158898709740775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000074/wf-form4_158898709740775.xml","form_type":"4"}},{"id":3156994,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-09T01:18:37.000Z","date":"2020-05-08","kind":"exercise","acquired":true,"shares":15000,"price":5.92,"value":88800.0,"ownership":{"direct":true},"balance_after":1097568,"source":{"system":"sec-edgar","filing":"0000939767-20-000074","document":"wf-form4_158898709740775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000074/wf-form4_158898709740775.xml","form_type":"4"}},{"id":3156993,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-09T01:18:37.000Z","date":"2020-05-08","kind":"exercise","acquired":true,"shares":30000,"price":4.58,"value":137400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1082568,"source":{"system":"sec-edgar","filing":"0000939767-20-000074","document":"wf-form4_158898709740775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976720000074/wf-form4_158898709740775.xml","form_type":"4"}},{"id":3290997,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2020-02-04T21:59:55.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":84632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":846320},"source":{"system":"sec-edgar","filing":"0001209191-20-006429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919120006429/doc4.xml","form_type":"4"}},{"id":3290996,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-04T21:59:55.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":846320,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":2039521,"source":{"system":"sec-edgar","filing":"0001209191-20-006429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919120006429/doc4.xml","form_type":"4"}},{"id":3331082,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-12-26T13:56:29.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":846320,"price":0.125,"value":105790.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":846320,"derivative":{"exercise_price":0.666,"exercise_date":"2019-12-24","expiration_date":"2024-12-24","underlying":"Common Stock","underlying_shares":846320},"source":{"system":"sec-edgar","filing":"0001209191-19-061858","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119061858/doc4.xml","form_type":"4"}},{"id":3331081,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2019-12-26T13:56:29.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":84632,"price":6.66,"value":563649.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":84632,"derivative":{"underlying":"Common Stock","underlying_shares":846320},"source":{"system":"sec-edgar","filing":"0001209191-19-061858","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119061858/doc4.xml","form_type":"4"}},{"id":3393537,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-15T20:45:14.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":46500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":46500,"derivative":{"exercise_price":0.64,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":46500},"source":{"system":"sec-edgar","filing":"0001209191-19-053167","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119053167/doc4.xml","form_type":"4"}},{"id":3483324,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-06-20T21:54:16.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":1905,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5095,"source":{"system":"sec-edgar","filing":"0001127602-19-022424","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219022424/form4.xml","form_type":"4"}},{"id":3512503,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2019-05-25T00:43:38.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":20634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date."}],"balance_after":20634,"derivative":{"exercise_price":19.77,"exercise_date":"2019-05-23","expiration_date":"2026-05-22","underlying":"Common Stock","underlying_shares":20634},"source":{"system":"sec-edgar","filing":"0000939767-19-000134","document":"wf-form4_155874500148985.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976719000134/wf-form4_155874500148985.xml","form_type":"4"}},{"id":3512502,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-25T00:43:38.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":10317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan.  The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1052568,"source":{"system":"sec-edgar","filing":"0000939767-19-000134","document":"wf-form4_155874500148985.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976719000134/wf-form4_155874500148985.xml","form_type":"4"}},{"id":3516691,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-21T20:46:13.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":370370,"price":0.125,"value":46296.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":370370,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":370370},"source":{"system":"sec-edgar","filing":"0001209191-19-031767","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119031767/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3516690,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-21T20:46:13.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":370370,"price":1.08,"value":399999.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":1189872,"source":{"system":"sec-edgar","filing":"0001209191-19-031767","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119031767/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3535059,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-08T21:13:31.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":370370,"price":0.125,"value":46296.25,"ownership":{"direct":true},"balance_after":370370,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":370370},"source":{"system":"sec-edgar","filing":"0001209191-19-028275","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119028275/doc4.xml","form_type":"4"}},{"id":3535058,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-08T21:13:31.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":370370,"price":1.08,"value":399999.6,"ownership":{"direct":true},"balance_after":1189872,"source":{"system":"sec-edgar","filing":"0001209191-19-028275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119028275/doc4.xml","form_type":"4"}},{"id":3639802,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2019-02-23T00:35:45.000Z","date":"2019-02-21","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012."}],"balance_after":0,"derivative":{"exercise_price":4.57,"exercise_date":"2012-05-24","expiration_date":"2019-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000939767-19-000048","document":"wf-form4_155088213177229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976719000048/wf-form4_155088213177229.xml","form_type":"4"}},{"id":3639801,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2019-02-23T00:35:45.000Z","date":"2019-02-21","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009."}],"balance_after":0,"derivative":{"exercise_price":4.16,"exercise_date":"2009-05-14","expiration_date":"2019-05-13","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0000939767-19-000048","document":"wf-form4_155088213177229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976719000048/wf-form4_155088213177229.xml","form_type":"4"}},{"id":3639800,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-23T00:35:45.000Z","date":"2019-02-21","kind":"sale","acquired":false,"shares":26250,"price":21.25,"value":557812.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.24 to $21.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4."}],"balance_after":1042251,"source":{"system":"sec-edgar","filing":"0000939767-19-000048","document":"wf-form4_155088213177229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976719000048/wf-form4_155088213177229.xml","form_type":"4"}},{"id":3639799,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-23T00:35:45.000Z","date":"2019-02-21","kind":"exercise","acquired":true,"shares":15000,"price":4.57,"value":68550.0,"ownership":{"direct":true},"balance_after":1068501,"source":{"system":"sec-edgar","filing":"0000939767-19-000048","document":"wf-form4_155088213177229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976719000048/wf-form4_155088213177229.xml","form_type":"4"}},{"id":3639798,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-23T00:35:45.000Z","date":"2019-02-21","kind":"exercise","acquired":true,"shares":11250,"price":4.16,"value":46800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":1053501,"source":{"system":"sec-edgar","filing":"0000939767-19-000048","document":"wf-form4_155088213177229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976719000048/wf-form4_155088213177229.xml","form_type":"4"}},{"id":3712848,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-02T21:12:34.000Z","date":"2018-12-28","kind":"purchase","acquired":true,"shares":50000,"price":1.0914,"value":54570.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.04 to $1.12 inclusive.  The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":835073,"source":{"system":"sec-edgar","filing":"0001209191-19-000242","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919119000242/doc4.xml","form_type":"4"}},{"id":3716801,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-28T21:21:12.000Z","date":"2018-12-27","kind":"purchase","acquired":true,"shares":26401,"price":1.0401,"value":27459.6801,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.04 inclusive.  The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":785073,"source":{"system":"sec-edgar","filing":"0001209191-18-064319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118064319/doc4.xml","form_type":"4"}},{"id":3716800,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-28T21:21:12.000Z","date":"2018-12-26","kind":"purchase","acquired":true,"shares":90000,"price":0.9542,"value":85878.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8796 to $1.10 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":758672,"source":{"system":"sec-edgar","filing":"0001209191-18-064319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118064319/doc4.xml","form_type":"4"}},{"id":3754362,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":4583,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.76,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754361,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.52,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754360,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":17.4,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754359,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":3051,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":74.4,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":3051},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754358,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":120.24,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754357,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":74.64,"expiration_date":"2024-05-21","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754356,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":1458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":111.84,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":1458},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754355,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":152,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the cancelled option were fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":31.92,"expiration_date":"2022-02-08","underlying":"Common Stock","underlying_shares":152},"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3754354,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T22:29:48.000Z","date":"2018-11-12","kind":"grant","acquired":true,"shares":20910,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I.  The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":168672,"source":{"system":"sec-edgar","filing":"0001209191-18-059793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059793/doc4.xml","form_type":"4"}},{"id":3758578,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T21:03:12.000Z","date":"2018-11-16","kind":"purchase","acquired":true,"shares":300000,"price":1.3849,"value":415470.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $1.36 to $1.41 inclusive.  The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":668672,"source":{"system":"sec-edgar","filing":"0001209191-18-059148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059148/doc4.xml","form_type":"4"}},{"id":3758577,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T21:03:12.000Z","date":"2018-11-15","kind":"purchase","acquired":true,"shares":200000,"price":1.3254,"value":265080.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $1.27 to $1.33 inclusive.  The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":368672,"source":{"system":"sec-edgar","filing":"0001209191-18-059148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118059148/doc4.xml","form_type":"4"}},{"id":3894737,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-06-14T21:27:50.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":1450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person transferred 5,831 shares that he directly owned to Esperanza Holdings, LLC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person transferred 12,375 shares that he directly owned to Stelios Holdings, LLC."}],"balance_after":3190,"source":{"system":"sec-edgar","filing":"0001127602-18-020950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218020950/form4.xml","form_type":"4"}},{"id":3904831,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T20:29:59.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first."}],"balance_after":55000,"derivative":{"exercise_price":0.73,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-18-035697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120919118035697/doc4.xml","form_type":"4"}},{"id":3919295,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2018-05-25T00:28:19.000Z","date":"2018-05-24","kind":"grant","acquired":true,"shares":15874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates."}],"balance_after":15874,"derivative":{"exercise_price":20.5,"exercise_date":"2018-05-24","expiration_date":"2025-05-23","underlying":"Common Stock","underlying_shares":15874},"source":{"system":"sec-edgar","filing":"0000939767-18-000108","document":"wf-form4_152720803868692.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976718000108/wf-form4_152720803868692.xml","form_type":"4"}}],"next_cursor":"2018-05-25T00:28:19.000000Z,3919295"}